Evidence map›Paper›PMID 31427291›Full record

ArticleAntimicrobial agents and chemotherapy2019

Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Shiqi Xiao, Haidan Guo, Warren S Weiner, Clinton Maddox, Chunhong Mao, Hendra Gunosewoyo, Shaaretha Pelly, E Lucile White, Lynn Rasmussen, Frank J Schoenen and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Shiqi XiaoCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Haidan GuoCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Warren S WeinerSpecialized Chemistry Center, University of Kansas, Lawrence, Kansas, USA.
Clinton MaddoxSouthern Research Molecular Libraries Screening Center, Southern Research Institute, Birmingham, Alabama, USA.
Chunhong MaoBiocomplexity Institute and Initiative, University of Virginia, Charlottesville, Virginia, USA.
Hendra GunosewoyoSchool of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Western Australia, Australia.
Shaaretha PellyCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
E Lucile WhiteSouthern Research Molecular Libraries Screening Center, Southern Research Institute, Birmingham, Alabama, USA.
Lynn RasmussenSouthern Research Molecular Libraries Screening Center, Southern Research Institute, Birmingham, Alabama, USA.
Frank J SchoenenSpecialized Chemistry Center, University of Kansas, Lawrence, Kansas, USA.
Jeffrey AubéSpecialized Chemistry Center, University of Kansas, Lawrence, Kansas, USA.
William R BishaiCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Shichun LunCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA slun1@jhmi.edu.
Johns Hopkins University · USSouthern Research Institute · USUniversity of Kansas · USJohns Hopkins Medicine · USCurtin University · AUUniversity of Virginia · US

Funding

University of Kansas Specialized Chemistry CenterU54HG005031 · NHGRI · UNIVERSITY OF KANSAS LAWRENCE · PI AUBE, JEFFREY · 2008 to 2013
$21.5M
Southern Research Specialized Biocontainment Screening Center (SRSBSC)U54HG005034 · NHGRI · SOUTHERN RESEARCH INSTITUTE · PI WHITE, E. LUCILE · 2008 to 2011
$10.4M
Screen for Synthetic Lethality in Mycobacterium TuberculosisR03MH084877 · NIMH · JOHNS HOPKINS UNIVERSITY · PI BISHAI, WILLIAM RAMSES · 2008 to 2008
$25k
NHGRI NIH HHS U54 HG005031NHGRI NIH HHS U54 HG005034NIAID NIH HHS HHSN272200900040CNIMH NIH HHS R03 MH084877
6 · The paper itself

Abstract

The suboptimal effectiveness of β-lactam antibiotics against

Indexed as

AnimalsAnti-Bacterial AgentsAntitubercular Agentsbeta-Lactamase Inhibitorsbeta-Lactamasesbeta-LactamsExtensively Drug-Resistant TuberculosisFemaleMeropenemMiceMice, Inbred BALB CMicrobial Sensitivity TestsMycobacterium tuberculosisSynthetic Lethal MutationsTuberculosis, Multidrug-ResistantAnti-Bacterial AgentsAntitubercular Agentsbeta-Lactamase Inhibitorsbeta-Lactamasesbeta-LactamsMeropenemhigh-throughput screensynthetic lethalitytuberculosisβ-lactams

Identifiers

PMID31427291
PMCPMC6811440
OpenAlexW2967890577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.